glp-1 drug interactions A Lithium Interaction Current Insights, Advantages and Challenges

Semaglutide is a once weekly subcutaneous injection, gradually titrated by your provider and documented in your patient portal

Discover how GLP-1 medications help fatty liver disease through clinical evidence, FDA-approved options, patient selection criteria, and monitoring protocols for MASLD and NASH treatment.

Do not reuse

Objective This systematic review aims to synthesise published evidence on respiratory adverse events temporally associated with GLP-1 RA therapy in adults, characterise their patterns and severity, appraise the risk of bias using validated design-appropriate tools, describe proposed pathophysiological mechanisms, and grade the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

To further note, in the field of weight-loss treatment, significant work is underway in parallel, on GIP agonist, amylin agonist, glucagon agonist, PYY agonist, either separately or in combination especially with GLP-1 agonist.